Please assess the completion status of the following clinical trial:

Trial Title: In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years,~* Fetal Infection with CMV authenticated by the positivity of the research of the viral genome by PCR in the amniotic liquid,~* Echographic Assessment revealing at least one cerebral extra anomaly being able to be in connection with the infection with CMV,~* Absence of request for termination of pregnancy from the start,~* Acceptance of a strict follow-up by a Multi-field Center of Prenatal diagnosis and of an optimal observance of the founded treatment,~* Collection of the written assent to take part in the test.~* Affiliation with a mode of social security or equivalent~Exclusion Criteria:~* No affiliation with a mode of social security (profit or having right)~* Patient of less than 18 years,~* Patient presenting another pathology obstetrical or medical (in particular hepatic or renal) preexistent to tracking or contra-indicating the use of valacyclovir,~* Patients whose fetus does not present any echographic sign being able to be in connection with the infection with CMV,~* Patients whose fetus presents at least one cerebral echographic anomaly:IntraparenchymalVentriculomegaly measured with the ventricular crossroads ≥ 12mm~  * Hyperechogenicity periventricular~ * Hydrocephaly~ * Intra-ventricular adherence~ * Microcephaly~ * Increase cuts large retro-cerebellar cistern~ * Hypoplasia vermis~ * Intraparenchymal calcifications~ * Porencephaly~ * Lissencephaly~ * Cysts periventricular~ * Hypoplasia of the callous body~ * Signs of LENTICULO-striated vasculopathy~* Patient under any other active antiviral treatment against CMV,~* Patient taking part in another therapeutic test,~* Patient refusing to sign the enlightened assent,~* Patient formulating a request for medical interruption of pregnancy before inclusion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZELITREX (Type: EXPERIMENTAL): ZELITREX
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).